EMD Serono

What EMD Serono does

EMD Serono, Inc. is the U.S. healthcare subsidiary of Merck KGaA, Darmstadt, Germany, operating as a specialty biopharmaceutical company focused on developing and commercializing therapies in neurology & immunology, fertility, oncology, and endocrinology. The company was founded in 1981 and employs 1,001–5,000 people, with corporate headquarters in Boston's Seaport District and an R&D Institute in Billerica, Massachusetts. Its marketed portfolio includes MAVENCLAD (cladribine tablets) and Rebif (interferon beta-1a) for multiple sclerosis; Gonal-f, Ovidrel, Cetrotide, and Pergoveris for fertility; BAVENCIO (avelumab) for urothelial carcinoma; TEPMETKO (tepotinib) for METex14-altered metastatic NSCLC; and Serostim for HIV-associated wasting. Technical differentiators include recombinant DNA technology (e.g., one of the first recombinant human FSH products), proprietary drug delivery devices such as the Redi-ject pen, and companion diagnostic integration (FoundationOne CDx for TEPMETKO patient selection).

The company operates a hybrid go-to-market model combining traditional prescription-based specialty distribution through healthcare providers, direct-to-consumer sales through the TrumpRx.gov platform for fertility drugs at up to 84% below list price, specialty pharmacy partnerships (CVS Health), and patient support programs such as MS LifeLines, Fertility Instant Savings, and the Embracing Carers initiative. EMD Serono monetizes through prescription drug sales rather than licensing or SaaS, with pricing models including most-favored-nation unit pricing on the TrumpRx channel and income-tiered discounts. The company is privately held under Merck KGaA, does not disclose standalone revenue, and is governed by its parent's strategic direction, as evidenced by a recent senior leadership transition in which Monia Vial succeeded Andrew Paterson as President of EMD Serono and Head of North America.

Name

EMD Serono

Legal name

EMD Serono, Inc.

Website

https://emdserono.com

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

EMD Serono is the U.S. healthcare subsidiary of Merck KGaA, developing and commercializing specialty biopharmaceuticals across neurology, immunology, fertility, oncology, and endocrinology for patients with difficult-to-treat conditions.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Specialty biopharmaceuticals
• Fertility treatments
• Multiple sclerosis therapies
• Oncology medications
• Endocrinology products

Headquarters

HQ city

Rockland

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales

Revenue model

1. Prescription Specialty Pharmaceuticals: EMD Serono generates revenue through the sale of prescription specialty pharmaceutical products including MAVENCLAD (cladribine tablets), Rebif (interferon beta-1a), Gonal-f, Ovidrel, Cetrotide, Serostim, BAVENCIO (avelumab), and TEPMETKO (tepotinib). Revenue is generated through traditional pharmaceutical distribution channels with healthcare providers prescribing to patients.
2. TrumpRx Direct-to-Consumer Sales: Following the agreement with the Trump administration in October 2025, EMD Serono sells fertility medications directly to consumers at significantly reduced prices through the TrumpRx.gov platform, with discounts of up to 84% below list price.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

EMD Serono develops, manufactures, and commercializes specialty biopharmaceutical products across five therapeutic areas: neurology and immunology (multiple sclerosis and myasthenia gravis treatments including MAVENCLAD and Rebif), fertility (Gonal-f, Ovidrel, Cetrotide, and Pergoveris for IVF and infertility treatment), oncology (BAVENCIO for urothelial carcinoma and Merkel cell carcinoma, TEPMETKO for metastatic NSCLC with METex14 alterations), and endocrinology (Serostim for HIV-associated wasting). The company also operates patient support programs, healthcare professional education, and direct-to-consumer access through the TrumpRx government platform.

Differentiator

Problem solved

Functional benefit

Brands

• Embracing Carers: A global initiative in collaboration with leading organizations to increase awareness, discussion and action about the often-overlooked needs of carers.
• MS LifeLines
• MAVENCLAD
• Rebif

Products and services

• MAVENCLAD (cladribine tablets) Short-course oral disease-modifying therapy for adults with relapsing forms of multiple sclerosis (RMS), also under clinical development for generalized myasthenia gravis. Prescribed by neurologists and dispensed through specialty pharmacy channels.
• Rebif (interferon beta-1a subcutaneous injection) Subcutaneous injectable disease-modifying therapy for relapsing forms of multiple sclerosis, supported by the MS LifeLines patient support program providing education, treatment information, and financial assistance.
• Gonal-f (follitropin alfa) Recombinant human follicle-stimulating hormone used to stimulate ovulation in women undergoing fertility treatment including IVF, administered via the proprietary Redi-ject pre-filled pen. Offered at significantly reduced prices through the TrumpRx platform.
• Ovidrel (choriogonadotropin alfa) Recombinant human chorionic gonadotropin used to trigger final follicular maturation and ovulation in fertility treatment cycles. Offered at significantly reduced prices through the TrumpRx platform.
• Cetrotide (cetrorelix) GnRH antagonist used to prevent premature ovulation during controlled ovarian stimulation in fertility treatment cycles. Offered at significantly reduced prices through the TrumpRx platform.
• Pergoveris (follitropin alfa and lutropin alfa) Combination therapy of recombinant human follicle-stimulating hormone and recombinant human luteinizing hormone for women with severe FSH and LH deficiency undergoing fertility treatment, currently filing for U.S. approval under expedited FDA review.
• BAVENCIO (avelumab) PD-L1 immune checkpoint inhibitor for treatment of locally advanced or metastatic urothelial carcinoma (first-line maintenance) and Merkel cell carcinoma, administered by healthcare professionals in oncology settings.
• TEPMETKO (tepotinib) Once-daily oral MET inhibitor for treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations, identified via the FDA-approved FoundationOne CDx companion diagnostic.
• Serostim (somatropin) Recombinant human growth hormone indicated for the treatment of HIV-associated wasting or cachexia in patients receiving antiretroviral therapy, supported by the AXIS Center patient support program.

Quantifiable outcome

• 6+ million IVF babies helped since first success
• +3 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

Eight partnerships are on record, tiered core.

• Foundation MedicinecoreTechnology or Integration · 21 May 2026FDA approved FoundationOne CDx as companion diagnostic for TEPMETKO (tepotinib) to identify metastatic NSCLC patients with METex14 skipping alterations. This marked the first time Foundation Medicine leveraged real-world data from its Flatiron Health-Foundation Medicine Clinico-genomic Database to support regulatory approval.
• Trump Administration / TrumpRxcoreGTM or Marketing Partner · 16 October 2025EMD Serono entered a most-favored-nation pricing agreement with the Trump administration to offer fertility therapies (Gonal-f, Ovidrel, Cetrotide) at up to 84% below list price through the TrumpRx.gov direct-to-consumer platform. The company also received exclusion from pharmaceutical tariffs in exchange for U.S. biopharmaceutical manufacturing investments. The agreement includes an FDA CNPV priority review voucher for Pergoveris.
• CVS HealthcoreChannel Partner/ Reseller/ Distributor · 16 October 2025CVS Health announced partnership in the TrumpRx Fertility program through its CVS Specialty Pharmacy, expected to launch January 2026. The program aims to reduce medicine costs and simplify access for patients requiring IVF medications, with Gonal-F available at 84% reduction.
• FDAcoreOthers · 16 October 2025EMD Serono received one of the first nine Commissioner's National Priority Review Vouchers (CNPVs) from FDA, enabling expedited review of Pergoveris fertility treatment filing.
• RESOLVE: The National Infertility AssociationcoreStrategic or Co-development PartnerEMD Serono collaborates with RESOLVE as a Visionary Partner and Corporate Council member to advance awareness, provide resources, and destigmatize infertility. The partnership focuses on patient education and support for people undergoing fertility treatment.
• Accelerated Cure Project for Multiple Sclerosis (ACP)coreStrategic or Co-development PartnerEMD Serono collaborates with ACP, a patient-founded non-profit dedicated to accelerating MS research, where individuals living with MS provide feedback on patient-reported outcome endpoints in clinical trials and patient-facing materials.
• Myasthenia Gravis Foundation of America (MGFA) and Myasthenis Gravis Association (MGA)coreStrategic or Co-development PartnerEMD Serono collaborates with MGFA and MGA for patient community engagement in myasthenia gravis, participating in MG-strong congresses and working to understand the rare autoimmune neuromuscular disorder better.
• Embracing Carers Global AdvisorscoreStrategic or Co-development PartnerGlobal initiative including advisors: Caregiver Action Network, Carers Australia, Carers Canada, Carers UK, Carers Worldwide, Eurocarers, National Alliance for Caregiving, International Alliance of Carer Organizations (IACO), Shanghai Roots & Shoots China. The initiative aims to increase global awareness, broaden stakeholder engagement, engage healthcare systems, and drive policy focus on caregiving.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• AbbVie: Specialty pharma leader with deep immunology (Humira/Skyrizi/Rinvoq) and women's health presence, operating at significantly broader scale across EMD Serono's therapeutic verticals.
• Sanofi (Specialty Care / Genzyme): Diversified global pharma whose specialty care unit focuses on rare diseases, neurology, and immunology, overlapping EMD Serono's neurology/immunology franchises at broader scale.
• Bayer (Pharmaceuticals): Diversified pharma with women's health, oncology, and specialty care units, offering broad-based overlap with EMD Serono's therapeutic mix.
• Novartis Pharmaceuticals: Large pharma with specialty oncology, neurology (Kesimpta, Mayzent in MS) and reproductive health assets, providing indirect competition across multiple EMD Serono therapeutic areas.

Direct peers

• Astellas Pharma: Specialty pharma with oncology, rare disease and women's health franchises, including targeted oncology therapies comparable to EMD Serono's TEPMETKO.
• Organon & Co: Women's-health focused specialty pharma built around reproductive health, fertility, and established brands; closely comparable to EMD Serono's fertility franchise and reproductive endocrinology business.
• Ipsen Biopharmaceuticals: Specialty pharma focused on oncology, neurology, and rare diseases; comparable therapeutic mix to EMD Serono and recent employer of EMD Serono's incoming President, indicating cultural overlap.
• Teva Pharmaceutical Industries: Specialty pharma with an MS franchise (Copaxone) and broad neurology/inflammation presence, directly comparable to EMD Serono's MS and immunology portfolio.
• Biogen: Specialty pharma with an MS franchise (Tysabri, Tecfidera, Avonex) and rare/neurology focus, directly comparable to EMD Serono's MS franchise and immuno-neurology pipeline.

Emerging players

• Swedish Orphan Biovitrum (Sobi): Rare-disease specialty pharma focused on immunology, neurology, and hematology; emerging player with partial overlap to EMD Serono's rare autoimmune (gMG) and inflammation pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/emdserono
• Facebookfacebook.com/myemdserono
• LinkedInlinkedin.com/company/emd-serono-inc
• Instagraminstagram.com/emdserono
• Xx.com/emdserono

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EMD Serono